Over three years, the women underwent Papanicolaou testing with colposcopy or biopsy if abnormalities were detected.
Among the 17,129 women who tested negative for HPV 16/18, the vaccine had an efficacy of 99 per cent for preventing HPV16/18-related cancerous cervical lesions.
In an intention-to-treat analysis of all women, the vaccine had an efficacy of 44 per cent.
Lancet 2007; 369:1,861-8
What do you think? Comment below or email firstname.lastname@example.org